Table 2 Comparison of maternal outcomes and hospital courses before and after PPH call implementation
Before a (n = 45) | After b (n = 66) | ||||
|---|---|---|---|---|---|
median (interquartile range) or frequency (%) | median (interquartile range) or frequency (%) | p-value | |||
Maternal death | 1 | (2%) | 0 | (0%) | > 0.99 |
Duration of hospital stay; days | 6 | (3.0–10.0) | 4 | (2.0–7.0) | 0.016 |
Duration of ICU stay; days | 0 | (0.0–1.5) | 0 | (0.0–1.3) | 0.686 |
Admission to ICU | 14 | (31%) | 17 | (26%) | 0.667 |
Duration of ICU admission; days | 2 | (1.8–2.0) | 2 | (2.0–2.8) | 0.294 |
Respirator use | 12 | (27%) | 12 | (19%) | 0.482 |
Duration of ventilator support; days | 0 | (0.0–1.0) | 0 | (0.0–0.0) | 0.367 |
AKI | 7 | (16%) | 3 | (5%) | 0.087 |
TACO/TRALI | 0 | (0%) | 0 | (0%) | 1.000 |
Hysterectomy | 3 | (7%) | 5 | (8%) | 1.000 |
Composite adverse events | 20 | (44%) | 20 | (30%) | 0.160 |
Blood transfusion initiation time; min | 68.5 | (31.5–144.3) | 16.0 | (9.0–66.0) | < 0.001 |
RBC volume; U | 6 | (2.0–10.0) | 6 | (1.5–12.0) | 0.825 |
FFP volume; U | 4 | (0.0–11.0) | 4 | (0.0–12.0) | 0.898 |
Treatment | 0.485 | ||||
Conservative treatment | 15 | (33%) | 19 | (29%) | |
TAE alone | 9 | (20%) | 9 | (14%) | |
Operation | 21 | (47%) | 38 | (58%) | |
Oxytocin | 23 | (51%) | 39 | (59%) | 0.441 |
Methylergometrine | 6 | (13%) | 8 | (12%) | 1.000 |
Uterine balloon | 5 | (11%) | 6 | (9%) | 0.755 |